The BioNTech SE ADR BNTX slid 2.22% to $106.32 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.29% to 5,983.99 and Dow Jones ...
The Goldman Sachs Group upgraded shares of BioNTech (NASDAQ:BNTX – Free Report) from a neutral rating to a buy rating in a ...
News Medical on MSN19h
Pfizer-BioNTech vaccine provides strong protection against MIS-C in children aged 5–17BioNTech vaccine’s role in preventing MIS-C, a rare post-COVID inflammatory syndrome in children. Study: Multisystem ...
German drugmaker BioNTech on Monday lowered its guidance for full-year revenue, citing COVID-19 uptake and price levels, ...
In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on BioNTech SE (BNTX – Research Report), with ...
Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future ...
Driven by the early approval of its updated COVID-19 vaccine, BioNTech far exceeded analysts’ expectations in the third ...
Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of ...
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, ...
Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...
The Centers for Disease Control and Prevention's (CDC's) 2024-2025 COVID-19 vaccine immunization schedule advises, in the ...
BioNTech reported EPS of 81 cents, up from 66 a year ago. “We successfully launched our variant-adapted COVID-19 vaccines upon receipt of earlier approvals as compared to last year.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback